Bipartisan Bill would Make Rare Pediatric Drug Incentive Permanent

A bipartisan group of House lawmakers has introduced legislation to permanently authorize an important federal incentive for rare pediatric drug development.

The Priority for Pediatric Cures Act, H.R. 10359, was introduced by Reps. Gus Bilirakis (R-FL), Nanette Barragán (D-CA), Kat Cammack (R-FL), Jake Auchincloss (D-MA), Tom Kean Jr. (R-NJ) and Kevin Mullin (D-CA).

The bill would remove the expiration provision from Section 529 of the Federal Food, Drug, and Cosmetic Act, making FDA’s Rare Pediatric Disease Priority Review Voucher Program permanent.  

How the program works 

A company receiving FDA approval for a qualifying rare pediatric disease drug or biologic may receive a priority review voucher. The company can use the voucher to obtain priority review of a different marketing application or sell it to another sponsor. 

Priority review generally provides a six-month FDA review goal rather than the standard 10-month goal. A voucher does not reduce FDA’s safety and effectiveness standards, guarantee approval or accelerate the clinical development of the pediatric treatment itself. 

Its value comes from potentially receiving a regulatory decision months earlier on another product. This makes the voucher a marketable asset that can help offset the difficult economics of developing a treatment for a very small patient population. 

Under current law and FDA guidance, FDA cannot award new vouchers after September 30, 2029. H.R. 10359 would eliminate that deadline. 

Implications for research and investment 

Rare pediatric diseases present significant development challenges. Patient populations may be small and geographically dispersed, disease progression poorly understood and validated biomarkers unavailable. Developers often must invest in natural-history studies, patient registries, specialized clinical sites, diagnostic testing and pediatric formulations before pivotal trials can begin. 

The possibility of earning a transferable voucher improves the potential return on that investment. It can help attract venture financing, support licensing transactions and encourage larger companies to acquire or partner on programs that otherwise appear commercially limited. 

A temporary program provides far less value. A therapy entering preclinical development today may have little chance of reaching approval before 2029. Investors therefore may discount the voucher when deciding whether to support the program. 

Permanent authorization would allow developers to incorporate the incentive into long-term planning with greater confidence. The bill’s sponsors report that FDA has awarded 63 vouchers, with more than 90% associated with diseases that previously had no approved treatment. 

Supporting commercialization 

For an emerging biotechnology company, selling a voucher after approval can generate capital to establish commercial operations, expand manufacturing, conduct post-approval studies or advance another rare-disease program. 

Potential voucher eligibility can also increase an asset’s value during venture financings, licensing negotiations and acquisitions. For academic researchers and patient-founded companies, it may strengthen the pathway from scientific discovery to a commercially viable development program. 

The voucher remains contingent: it is awarded only after approval and has no value if development fails. Market prices also fluctuate, and companies are not required to reinvest sale proceeds in rare-disease research. 

A Government Accountability Office review previously found it was too early to determine the program’s effectiveness, given the lengthy drug-development process. Critics have also raised concerns about FDA workload and vouchers being used for unrelated products. Those issues justify continued reporting and evaluation, but not repeated uncertainty over whether the program will survive. 

A durable commitment to pediatric innovation 

Most of the thousands of identified rare diseases still lack an FDA-approved treatment, and many primarily affect children. Conventional commercial incentives are often insufficient to support the years of research required for very small patient populations. 

The Priority for Pediatric Cures Act would not solve every scientific, regulatory or reimbursement challenge. It would preserve an important source of commercial value and remove an avoidable uncertainty from research planning. 

MichBio supports permanent authorization of the Rare Pediatric Disease Priority Review Voucher Program and encourages Michigan’s congressional delegation to join this bipartisan effort. Researchers, companies and families should be able to plan around a durable national commitment, not another approaching expiration date.